---
title: "YZYBIO-B: Mid-term data from the Phase II study of M701 for malignant pleural effusion will be announced at the 2025 ESMO conference"
description: "YZYBIO-B announced that the mid-term data of its bispecific antibody M701 in the Phase II clinical study for the treatment of malignant pleural effusion caused by advanced non-small cell lung cancer h"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261766549.md"
published_at: "2025-10-19T10:22:02.000Z"
---

# YZYBIO-B: Mid-term data from the Phase II study of M701 for malignant pleural effusion will be announced at the 2025 ESMO conference

> YZYBIO-B announced that the mid-term data of its bispecific antibody M701 in the Phase II clinical study for the treatment of malignant pleural effusion caused by advanced non-small cell lung cancer has been presented at the 2025 European Society for Medical Oncology (ESMO). The study is a randomized, controlled, multicenter, open-label trial, with the primary endpoint being puncture-free survival time, and secondary endpoints including the objective response rate of malignant pleural effusion. As of March 7, 2025, a total of 54 patients participated, with 26 in the experimental group and 28 in the control group

According to the news from Zhitong Finance APP, YZYBIO-B (02496) announced that the mid-term data of its self-developed dual-target bispecific antibody (Bs Ab) drug M701, which targets epithelial cell adhesion molecule (Ep CAM) and cluster of differentiation 3 (CD3), in a Phase II clinical study for the treatment of malignant pleural effusion caused by advanced non-small cell lung cancer (NSCLC) in China has been presented in the form of a conference poster at the 2025 European Society for Medical Oncology (ESMO) (poster number: 1880P), and will also be published on the company's website (https://www.yzybio.com).

This study is a randomized, controlled, multicenter, open-label Phase II clinical trial (development code: M70103) targeting malignant pleural effusion caused by advanced non-small cell lung cancer (NSCLC). The study enrolled subjects in a 1:1 ratio into the experimental group and the control group. Subjects in the experimental group received intrathoracic infusion of M701 after thoracentesis drainage, while subjects in the control group received intrathoracic infusion of cisplatin after thoracentesis drainage. The primary endpoint of the study is puncture-free survival time (Pu FS), defined as the time from the end of treatment to the occurrence of intolerable malignant pleural effusion or death, which is a composite event time endpoint that directly reflects the control time of local treatment for malignant pleural effusion. The secondary endpoints of the study include the objective response rate (ORR) of malignant pleural effusion, time to next puncture (TTNP), symptoms and signs related to malignant pleural effusion, pharmacodynamics, and immunogenicity.

As of March 7, 2025, 54 eligible patients with advanced non-small cell lung cancer (NSCLC) who had progressed after at least one line of systemic treatment and had symptomatic malignant pleural effusion were randomly assigned in a 1:1 ratio, with 26 in the experimental group and 28 in the control group. The median age of the experimental group was 66.5 years, while the median age of the control group was 61.5 years. The proportion of females in the experimental and control groups was 57.7% and 50.0%, respectively. The proportion of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 was 92.3% and 96.4%, respectively. The proportion of patients with baseline pleural effusion volume of medium or above (≥500mL) was 65.4% and 67.9%, respectively. The proportion of patients who had previously undergone thoracentesis treatment was 65.4% and 71.4%, respectively. The proportion of patients with positive driver gene mutations was 76.9% and 78.6%, respectively. The proportion of patients who had previously received intrathoracic chemotherapy was 42.3% and 35.7%, respectively. Except for the older age of the experimental group, the baseline characteristics of the two groups were relatively balanced.

**Efficacy Results:** The puncture-free survival time of the experimental group was longer than that of the control group (median 130 days vs. 85 days, HR (hazard ratio) = 0.80, p = 0.542), while for patients with negative driver gene mutations (median not reached vs. 44.5 days, HR < 0.01, p < 0.001) or those with a history of intrathoracic chemotherapy (median 253 days vs. 72 days, HR = 0.31, p = 0.076), the benefits were more significant. In the aforementioned populations, the objective response rates (MPE ORR) of malignant pleural effusion in the experimental and control groups were 72.7% and 41.7%, respectively After 98 days of random grouping, only the experimental group showed continuous improvement in dyspnea symptoms. Flow cytometry analysis indicated a significant reduction in Ep CAM+CD45- tumor cells in the pleural effusion after M701 infusion, while no such phenomenon was observed in the control group receiving cisplatin.

**Safety Results:** The incidence of treatment-related adverse events for M701 was 3.7%, compared to 10% in the cisplatin group, with only one serious adverse event (grade 2 fever) related to M701.

**Conclusion:** Compared to cisplatin, M701 pleural infusion demonstrated significant efficacy in treating malignant pleural effusion and showed good tolerance, supporting its further clinical development, especially for non-small cell lung cancer (NSCLC) patients without driver gene mutations or those who have previously received intrathoracic chemotherapy. This Phase II trial is still ongoing and has shown considerable potential in preventing the recurrence of pleural effusion, particularly in driver gene-negative NSCLC patients or those who have previously undergone intrathoracic chemotherapy. Based on the current excellent results, a pivotal Phase III trial is planned to start in 2026 to validate its efficacy and safety in a large Chinese population

### Related Stocks

- [02496.HK - YZYBIO-B](https://longbridge.com/en/quote/02496.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 武漢友芝友生物製藥公司獲得 FDA 批准其雙特異性抗體 M701 用於治療惡性胸腔積液的 IND 申請 | 武漢友芝友生物科技有限公司已獲得 FDA 對其 M701 的臨牀試驗新藥申請的批准，該藥物是一種雙特異性抗體，靶向 EpCAM 和 CD3。此批准允許在美國進行針對晚期上皮腫瘤患者的惡性胸腔積液的 Ib/II 期臨牀試驗。該公司旨在滿足腫瘤 | [Link](https://longbridge.com/en/news/274639663.md) |
| 新加坡發佈了指導方針，以幫助家庭醫生管理患者的更年期問題 | 新加坡已發佈首套關於更年期過渡管理的指南，以幫助醫療專業人員管理 45 至 65 歲女性的更年期症狀。這些指南解決了初級保健醫生在診斷和治療更年期方面缺乏信心的問題，這一點在 2025 年的一項研究中得到了強調。高級部長沈穎強調了需要進行文 | [Link](https://longbridge.com/en/news/276430476.md) |
| 15:02 ET Julian Circo 正在通過引入 AI 技術來顛覆慢性咳嗽這一世界上最古老的症狀 | Julian Circo，Hyfe 的聯合創始人，在《Disruption Interruption》播客中討論了他的公司如何通過使用人工智能將咳嗽轉化為客觀生物標誌物，從而革新呼吸道診斷。Hyfe 已收集超過 7 億個咳嗽樣本，旨在通過一 | [Link](https://longbridge.com/en/news/276373106.md) |
| Collage 成為加拿大首個嵌入 Nmbr 驅動的薪資功能的福利關聯 HR 平台 | Collage 推出了 Collage Payroll，成為加拿大首個將薪資管理嵌入的福利連接人力資源平台，合作伙伴為 Nmbr。此項整合使企業能夠通過一個平台管理人力資源、薪資和福利，從而減少行政負擔和錯誤。該合作旨在簡化加拿大企業的薪資 | [Link](https://longbridge.com/en/news/276121845.md) |
| Healthcare Realty Trust (HR) 的 12 億美元投資組合調整是否重新定義了其核心投資理念？ | Healthcare Realty Trust 公佈了 2025 年第四季度的業績，收入為 2.863 億美元，淨收入為 1439 萬美元。公司宣佈 2026 年每股收益指導在虧損 0.05 美元到盈利 0.05 美元之間，並計劃每股派發  | [Link](https://longbridge.com/en/news/275984316.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.